Despite Panel Thumbs-Up, Analysts Downplay Absorb Market Impact
This article was originally published in The Gray Sheet
Executive Summary
While a panel of FDA experts almost unanimously voted to recommend Abbott's fully bioabsorbable Absorb scaffold, analysts say the stent is unlikely to take significant market share, at least in its current form.